Trientine Dihydrochloride

The goal of drug therapy in individuals with Wilson Disease is to remove excess copper from the body and prevent ongoing copper accumulation. Drug therapy therefore must be life long.

Trientine Dihydrochloride, also referred to as Trientine hydrochloride or Triethylenetetramine dihydrochloride (structure:C6H1sN4.2HCl :molecular weight 219.16), is a chelating agent. Excess copper is chelated (or bonded) by forming a stable complex with Trientine and is excreted from the body via the urinary excretion.

Trientine is indicated especially in Wilson Disease patients who are intolerant to D-penicillamine or have clinical features indication potential intolerance.

Following the grant of product license in the United Kingdom in 1985 by the MHRA, Trientine was also designated as an Orphan Medicinal product in 2003 by the European Agency for the Evaluation of Medicinal Products (EMEA) on the basis of increased availability to patients and excellent drug safety profile.

Summary of Product Characteristics contains all relevant prescribing information about Trientine capsules.

 

Treatment Compliance.

Taking your Trientine capsules according to your physician's instruction is particularly important to successfully managing Wilson's Disease; even if you do not show any symptoms in the case of asymptomatic patients.

It has been estimated that approximately 10-50% of patients on medical therapy for Wilson's Disease have periods of non adherence (1). Discontinuation of treatment can lead to hepatic inflammation and damage, neurological and psychiatric compromise, hepatic failure, and death. For those that survive, the injury resulting from non adherence leads to lengthy and costly hospitalizations, physical disability, and the need for rehabilitative and other chronic care services.

Wilson's Disease is a very treatable condition and many patients live a normal life expectancy which is made possible by taking their medicine as prescribed by their physician.

Roberts,E.; Schilsky, ML. A practice guideline on Wilson Disease. Hepatology 2003;37:1475-92

 

 This website is intended for information purposes only.

Each patient is strongly advised to consult with their physician about their individual cases.

Latest News

EASL publishes Clinical Practice Guidelines for Wilson Disease
4th March 2014
The European Association for the study of the Liver (EASL) has published a Clinical Practice Guidelineā€¦ more...
February's News
News Archive